Biotech Due Diligence › Metrics
Key Metrics for Biotech Startups: Investor Benchmarks & Benchmarks (2026)
These 4 metrics are what institutional investors evaluate when screening Biotech startups. Each metric is accompanied by benchmark ranges sourced from our database of 2+ comparable company analyses.
01. Clinical Stage
IND Filed → Phase I → Phase II → Phase III → FDA Submission
Each stage transition is a major de-risking milestone
02. Target Patient Population
Rare disease: >200K US patients | Broad indication: millions
Rare disease (orphan) designation offers faster FDA path and market exclusivity
03. Preclinical Efficacy Data
In vivo (animal) studies with validated disease models
In vitro data alone is insufficient for investment decisions
04. IP Protection
Core composition-of-matter patents with >10 years of exclusivity
Patent expiry timeline determines commercial window
How DDR Benchmarks These Metrics
When you upload a Biotech startup pitch deck, DDR automatically:
- Extracts all Biotech metrics from every slide of the pitch deck
- Benchmarks each metric against 2 comparable Biotech companies
- Flags metrics outside healthy ranges as red flags with severity weighting
- Provides an overall verdict (INVEST / DIG DEEPER / PASS) with score 1–10
- Generates expected return scenarios based on Biotech exit data
Biotech Due Diligence — All Guides
AUTOMATE YOUR BIOTECH DUE DILIGENCE
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →